Young Hak Kim
Overview
Explore the profile of Young Hak Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
2754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jo J, Koo H, Kang J, Kim Y, Yang D
Am J Cardiol
. 2024 Dec;
239:82-89.
PMID: 39672486
We aimed to compare artificial intelligence (AI)-based coronary stenosis evaluation of coronary computed tomography angiography (CCTA) with its quantitative counterpart of invasive coronary angiography (ICA) and invasive fractional flow reserve...
2.
Yoshioka H, Ishida T, Atagi S, Tamiya A, Nishimura T, Iwamoto Y, et al.
Clin Lung Cancer
. 2024 Oct;
26(1):1-8.
PMID: 39482146
Background: We conducted a randomize phase II study to evaluate the efficacy and safety of topoisomerase II inhibitor amrubicin plus topoisomerase I inhibitor irinotecan (AI) compared with cisplatin plus irinotecan...
3.
Sawada R, Nishioka N, Kim Y, Kiyomi F, Uchino J, Takayama K
Transl Lung Cancer Res
. 2023 Sep;
12(8):1802-1806.
PMID: 37691860
Background: The combination of erlotinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and ramucirumab, an anti-vascular endothelial growth factor receptor (VEGFR) antibody, is one of the most...
4.
Atagi S, Daimon T, Okishio K, Komuta K, Okano Y, Minato K, et al.
Thorac Cancer
. 2023 Aug;
14(29):2941-2949.
PMID: 37609677
Background: This study evaluated the efficacy and safety of the combination chemotherapy of docetaxel plus S-1 in patients with previously treated non-small cell lung cancer (NSCLC) compared to docetaxel alone....
5.
Nakamura R, Fujii H, Yamada T, Matsui Y, Yaoi T, Honda M, et al.
JTO Clin Res Rep
. 2023 Jul;
4(6):100525.
PMID: 37426308
Introduction: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the...
6.
Kawachi H, Yamada T, Yoshimura A, Morimoto K, Iwasaku M, Tokuda S, et al.
Ther Adv Med Oncol
. 2023 Jun;
15:17588359231177022.
PMID: 37333903
Background: Osimertinib is a standard treatment option for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, osimertinib monotherapy yields poor clinical outcomes in some patients, necessitating...
7.
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, et al.
Drugs Aging
. 2023 May;
40(6):563-571.
PMID: 37145245
Background: Programmed death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy is used as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), regardless of age. Objective: We examined the role...
8.
Morita-Tanaka S, Miyagawa-Hayashino A, Yamada T, Matsui Y, Morimoto K, Hiranuma O, et al.
Support Care Cancer
. 2023 Apr;
31(5):308.
PMID: 37115357
Purpose: Growth differentiation factor-15 (GDF-15) is one of the key cachexia-inducing factors. Clinical trials on therapies targeting GDF-15 for cancer and cancer cachexia are underway. While the role of circulating...
9.
Ishida M, Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, et al.
JTO Clin Res Rep
. 2023 Apr;
4(4):100493.
PMID: 37025120
Introduction: In recent years, programmed cell death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy was found to have favorable clinical outcomes in patients with extensive-stage SCLC (ES-SCLC). The usefulness of early...
10.
Katayama Y, Yamada T, Morimoto K, Fujii H, Morita S, Tanimura K, et al.
JTO Clin Res Rep
. 2023 Apr;
4(4):100494.
PMID: 37020925
Introduction: Lung adenocarcinoma with negative TTF-1 expression is believed to be a poor prognostic factor for certain systemic treatments. Nevertheless, the impact of TTF-1 expression on combined chemoimmunotherapy remains unclear....